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ABSTRACT
Objective: Assessing the effectiveness of the
Assessment of Burden of COPD (ABC) tool on disease-
specific quality of life in patients with chronic
obstructive pulmonary disease (COPD) measured with
the St. George’s Respiratory Questionnaire (SGRQ),
compared with usual care.
Methods: A pragmatic cluster randomised controlled
trial, in 39 Dutch primary care practices and 17
hospitals, with 357 patients with COPD
(postbronchodilator FEV1/FVC ratio <0.7) aged
≥40 years, who could understand and read the Dutch
language. Healthcare providers were randomly
assigned to the intervention or control group. The
intervention group applied the ABC tool, which
consists of a short validated questionnaire assessing
the experienced burden of COPD, objective COPD
parameter (eg, lung function) and a treatment
algorithm including a visual display and treatment
advice. The control group provided usual care.
Researchers were blinded to group allocation during
analyses. Primary outcome was the number of
patients with a clinically relevant improvement in
SGRQ score between baseline and 18-month follow-
up. Secondary outcomes were the COPD Assessment
Test (CAT) and the Patient Assessment of Chronic
Illness Care (PACIC; a measurement of perceived
quality of care).
Results: At 18-month follow-up, 34% of the 146
patients from 27 healthcare providers in the
intervention group showed a clinically relevant
improvement in the SGRQ, compared with 22% of the
148 patients from 29 healthcare providers in the
control group (OR 1.85, 95% CI 1.08 to 3.16). No
difference was found on the CAT (−0.26 points
(scores ranging from 0 to 40); 95% CI −1.52 to
0.99). The PACIC showed a higher improvement in
the intervention group (0.32 points (scores ranging
from 1 to 5); 95% CI 0.14 to 0.50).
Conclusions: This study showed that use of the ABC
tool may increase quality of life and perceived quality
of care.
Trial registration number: NTR3788; Results.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is a chronic disease with millions of
sufferers worldwide. This number is expected
to increase, mainly due to an ageing popula-
tion and an increase in smoke exposure in
women.1–3
COPD has a major impact on daily life and
quality of life that goes beyond airway limita-
tion.4–8 The Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guideline
Strengths and limitations of this study
▪ This study was a pragmatic study, which makes
the results more applicable to daily care.
▪ The study was executed nationwide in primary
and hospital care.
▪ Owing to the design of the study, no blinding
and allocation concealment was possible.
▪ Owing to the pragmatic design, not all data were
reported that were necessary to perform all
analyses.
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recommends a combined assessment of COPD using the
so-called ‘ABCD’ classiﬁcation model, which, apart from
spirometry, assesses future risk (exacerbations) and
current burden/impact of disease using questionnaire
data.3 However, tools advocated to assess the burden of
COPD only measure a limited number of aspects and do
not provide a visual display to educate and involve
patients in their treatment. Perhaps even more import-
antly, the way in which to make use of the patient-
reported outcomes or the impact of assessing the
burden of disease in this way on outcomes of care has
not been tested at all. Therefore, the Assessment of
Burden of COPD (ABC) tool was developed,9 an innova-
tive tool measuring and visualising integrated health
status. An important part of the tool is the ABC scale
(see online supplementary appendix A), which is largely
based on the Clinical COPD Questionnaire (CCQ),10
and which measures the experienced burden of COPD.
The CCQ was adapted by adding 4 questions to the exist-
ing 10 questions, to comply with the deﬁnition of
burden of COPD, which was formulated by an expert
team and conﬁrmed by patients and healthcare provi-
ders.9 The ABC scale consists of ﬁve domains (ie, symp-
toms, functional state, mental state, emotions and
fatigue)9 and shows excellent reliability and validity.11
This scale is combined with other parameters (ie, lung
function, exacerbations, body mass index, comorbidity,
smoking status and self-reported level of physical activ-
ity) to assess the integrated health status of a patient
with COPD. The ABC tool visualises the outcome (using
balloons, see ﬁgure 1) and therewith promotes aware-
ness for patient and healthcare provider, and offers a
treatment algorithm. Moreover, it provides the oppor-
tunity to support personalised care planning including a
personal treatment goal. When a balloon is selected, an
evidence-based treatment advice is shown, which the
patient and healthcare provider can discuss. They can
then decide on a treatment plan together through
shared decision-making (see box 1).
The majority of treatment options include lifestyle
changes, such as smoking cessation and increasing phys-
ical activity, which requires commitment, engagement
and self-management skills of patients.12 13 The ABC
tool can be used as a communication tool in primary
and hospital care (ie, in patients with mild/moderate
and severe/very severe COPD), and it also provides the
opportunity to monitor progression or deterioration by
displaying the balloons of previous visits in grey (see
ﬁgure 1). We hypothesised that giving patients the possi-
bility and the responsibility in setting personal treatment
goals and making their own treatment plan will inﬂu-
ence self-management, facilitate and stimulate behav-
ioural change, and eventually lead to an improved
quality of life.
The primary aim of this study was to assess the effect-
iveness of using the ABC tool in patients with COPD on
disease-speciﬁc quality of life based on the St. George’s
Respiratory Questionnaire (SGRQ),14 over a period of
18 months compared with a control group receiving
usual care.
Figure 1 Visualisation of the integrated health status of a patient with COPD. The green balloons towards the top of the
figure indicate a satisfactory score in that domain, whereas the red balloons signify a low score and orange balloons an
intermediate score. Grey balloons are the balloons of previous visits which provide the opportunity to monitor over time. The five
domains of experienced burden of COPD, as measured with the ABC scale, are represented by the last five balloons, symptoms,
functional status, mental status, fatigue and emotions. Dyspnoea (evaluated by the Medical Research Council (MRC) scale18)
and level of physical activity are also reported by the patients. Smoking status, exacerbations, body mass index (BMI) and lung
function are reported by the healthcare providers.
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Secondary outcomes were quality of life based on the
COPD Assessment Test (CAT)15 and the patients’ per-
ceived quality of care as assessed with the Patient
Assessment of Chronic Illness Care (PACIC).16
METHODS
Study design, setting and patients
The current study was a pragmatic, two-armed, cluster
randomised controlled trial, conducted in 56 healthcare
centres (39 primary care, 17 hospital care) across
the Netherlands from March 2013 to May 2015
(Netherlands Trial Register, NTR3788). Ethics approval
was obtained from the Medical Ethics Committee of
Zuyderland Hospital, Heerlen, the Netherlands. A
detailed protocol of this study has been published else-
where.17 Informed consent was signed by patients prior
to enrolment.
Healthcare providers were recruited by the research-
ers, with no speciﬁc criteria or prerequisites. These
healthcare providers recruited patients, who were eli-
gible to participate if they had a spirometry-conﬁrmed
diagnosis of COPD (postbronchodilator FEV1/FVC
<0.7), were 40 years of age or over and could understand
and read the Dutch language. Exclusion criteria were as
follows: exacerbation <6 weeks before initiation of the
study, an addiction to hard drugs, a life-threatening
comorbid condition or pregnancy at the start of the
study.17 Eligibility criteria were checked by the health-
care providers.
Randomisation and masking
We randomised at the level of healthcare providers to
prevent contamination. Block randomisation of health-
care centres (random blocks of 2, 4 and 6), stratiﬁed by
healthcare setting (ie, primary vs hospital care), was per-
formed by the researchers using a computer program
developed by the Maastricht University Centre for Data
and Information Management (MEMIC). Blinding of
healthcare professionals and patients was not possible
due to the nature of the intervention, but the study
team was blind to the nature of the treatment arms in
the dataset. Unblinding was performed after unanimous
agreement on data cleaning, handling of missing data,
statistical analyses and conclusions drawn for the
primary outcome.
Intervention
Healthcare providers (ie, general practitioners (GPs),
practice nurses, pulmonologists and nurse specialists)
were instructed to use the ABC tool during their routine
consultations. As described in the study protocol,
patients should visit their healthcare providers at least
four times during the 18-month follow-up.17 Therefore,
healthcare providers were instructed to invite patients
for consultation at least once every 6 months. In each
consultation, patients were asked to ﬁll out the ABC
scale,9 report their dyspnoea using the Medical Research
Council (MRC) dyspnoea scale18 and self-report their
level of physical activity. Healthcare providers were
instructed to obtain some additional parameters (ie,
lung function, exacerbations, body mass index,
comorbidity and smoking status) and enter these into
the computer program. The program displayed the
results as balloons (see ﬁgure 1 for an example). The
colours and altitude of the balloons and corresponding
implications could then be discussed, and consequently,
patients and healthcare providers could decide on a
treatment plan together. Patients were encouraged to
formulate a personal treatment goal, in their own words,
and a speciﬁc treatment plan in accordance with this
goal (box 1 provides an example). It was possible to
print out an overview of the balloons, the personal goal
and the treatment plan at the end of the consultation.
The ABC tool is also meant to be used to monitor
patients’ health status: previous results are displayed
using grey balloons, resulting in the possibility to discuss
progress and deterioration of different parameters and
to evaluate treatment success.
Control
Healthcare providers in the control group were in-
structed to provide care as usual to their patients, as
described in the Dutch COPD healthcare guidelines.19 20
These guidelines are in line with guidelines from the
European Respiratory Society, the American Thoracic
Society4 and the GOLD3 guideline. The ABC scale and
tool were not used in the control group.
Measurements
Health-related quality of life data were collected at four
different points in time: at baseline and at 6-month,
12-month and 18-month follow-up. A set of question-
naires, that is, SGRQ, CAT and PACIC, was sent by the
researchers and completed by patients at home without
supervision, either on paper or online (as preferred by
the patient). Patients received reminders if they had not
returned the questionnaires within 3 weeks.
Box 1 Example of a patient’s personal goal and treatment
plan
Patient Ms A
This patient completed the Assessment of Burden of COPD (ABC)
scale, the Medical Research Council (MRC) scale and reported
her level of physical activity. Additional parameters were reported
by the healthcare provider. The ABC tool is shown in figure 1.
The patient decides, together with the general practitioner (GP),
to increase her level of physical activity.
Treatment plan:
Patient will raise her level of physical activity. Evaluation in
3 months.
Personal goal:
Walking my dog, three times a day, every day, for at least 15 min
each time.
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The SGRQ21 22 is a disease-speciﬁc measure of health
status with scores ranging from 0 to 100 (=maximum
impairment). Missing data were handled as described in
the SGRQ Manual.23
The CAT is another disease-speciﬁc questionnaire with
scores ranging from 0 to 40, where higher scores indi-
cate greater impairment of health-related quality of life.
Scores were calculated if no more than two items were
missing.15
The PACIC is a validated questionnaire that assesses
patients’ perceptions of the quality of care they have
received in the past 6 months. Scores range from 1 to 5,
with higher scores representing higher perceived quality
of care.16 As no speciﬁc missing data rules are provided
for the PACIC, it was decided to only include patients in
the analyses if at least 50% of the questions were
completed.24
Objective parameters (ie, lung function and exacerba-
tions) were entered by the healthcare providers into the
registration system developed for this trial. Reminders
to report the outcomes were sent twice during the
18-month follow-up.
Outcomes
The primary outcome measure was a clinically relevant
improvement on the SGRQ,14 deﬁned as a decrease of
at least four points on the total score of the SGRQ
between baseline and the 18-month follow-up.
Secondary outcomes were as follows:
1. Clinically relevant improvement on the SGRQ
between baseline and 6 months and between baseline
and 12 months.
2. Clinically relevant deterioration on the SGRQ between
baseline and 6 months, baseline and 12 months and
baseline and 18 months.
3. SGRQ total score at 18 months.
4. CAT score at 18 months.
5. PACIC score at 12 months and at 18 months.
According to our research protocol,17 two other clinical
outcomes were to be used, that is, lung function and
exacerbation rate. Data for these analyses had to be
reported by healthcare providers. However, in the control
group, these data were reported for only one-third of the
patients, a problem encountered because of the pragmatic
design of the study. Owing to this large amount of missing
data, it was decided not to address these two outcomes.
Sample size
The sample size calculation17 indicated that a total of
360 patients (180 patients per arm) were required to
detect a difference in the response rate on the primary
outcome between the intervention and control group
(ie, 50% vs 30% patients with a clinically relevant
improvement of at least four points in the intervention
group and control group, respectively14), with an
attrition rate of 25%, a power of 80% to detect this
difference and a two-tailed α of 5%. We estimated that
40 GPs (average of 5 patients per GP) and 20
pulmonologists (average of 8 patients per pulmonolo-
gist) were required. A detailed description of the
sample size calculation can be found in online supple-
mentary appendix B.
Statistical analyses
Data were analysed according to the intention-to-treat
principle, that is, all available data of all randomised
healthcare providers and patients were included in the
analysis, using maximum likelihood inference with
mixed regression for repeated measures. To address the
primary outcome and the ﬁrst two secondary outcomes
(see above), change scores in the SGRQ were calculated
by subtracting the baseline score from the scores at the
6-month, 12-month and 18-month follow-up. These
change scores were then dichotomised into improved
(ie, a decrease of four points or more on the SGRQ
total score14) versus not improved, and into deteriorated
(ie, an increase of four points or more on the SGRQ
total score14) versus not deteriorated. The relationship
between treatment and SGRQ improvement (yes or no)
was then analysed with mixed logistic regression, taking
into account that the times of measurement (change
after 6, 12 and 18 months) were nested within patients,
and patients were nested within healthcare providers
(three levels). Treatment arm (ie, intervention group vs
control group), time, treatment by time interaction and
covariates were incorporated into the model as predic-
tors. Covariates included in the analyses were age, sex,
smoking status at baseline and healthcare setting (ie,
primary care vs hospital care). This analysis was repeated
three times for the outcome clinically relevant SGRQ
improvement yes/no, with 18 months (primary outcome)
and 6 and 12 months (secondary outcomes) as reference
time points, respectively, in order to estimate and test the
treatment effect in a simple way for each time point
(primary: 18 months, secondary: 6 and 12 months).
The same analyses were repeated for the outcome
clinically relevant SGRQ deterioration yes/no.
To address the other secondary outcomes—the SGRQ
total score, CAT total score and PACIC total score—
analyses were performed with mixed linear regression,
with cluster, patient and measurements as three levels.
Predictors used in the model were time using dummy
coding with baseline as the reference category, and
dummy indicators for the 12-month and 18-month
follow-up, and for SGRQ and CAT also a dummy in-
dicator for the 6-month follow-up, treatment by time
interaction and the same covariates as mentioned above.
The interaction effect of treatment with the dummy indi-
cator for 18 months represents the group difference in
change from baseline to 18 months, and likewise for the
other two treatment by time dummy interaction terms.
Further, given that baseline is the reference time point,
the treatment effect itself is the group difference at base-
line (0 months), which can be expected to be zero due
to the randomised treatment assignment. If this treatment
effect was indeed not signiﬁcant, then it was removed
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from the mixed model. The treatment by time interaction
effect then became equivalent to the treatment effect at
follow-up adjusted for the baseline as a covariate.25–27
The primary treatment effect and the effect on im-
provement after 6 and 12 months were tested using
α=0.05 (two-tailed) following the protocol. However, in
view of multiple testing, treatment effects on the other
secondary outcomes were required to be signiﬁcant at
α=0.01. All analyses were performed using IBM SPSS
Statistics for Windows, V.21.0.
Sensitivity analyses
For the purpose of sensitivity analysis for the primary
outcome, a mixed logistic regression analysis was also
performed on only those patients for whom an SGRQ
score at baseline and at 18 months had been recorded,
allowing computation of change without borrowing
information from other patients or other points in time
in case of a missing value at 18 months. Hence, patients
were nested in clusters and the dependent variable was a
dichotomous change score at 18 months (ie, improved
vs not improved). The results of this analysis were com-
pared with those of the intention-to-treat analysis includ-
ing all available measurements of all patients.
RESULTS
A total of 62 healthcare providers were randomised into
the two treatment groups: 42 from primary care and 20
from hospital care. Three healthcare providers from
primary care and three from hospital care did not
include any patients. Figure 2 shows the study ﬂow chart
with the number of healthcare providers and patients
included in the study and randomised in the interven-
tion or control group. In the intervention group, the
average age of the healthcare providers was 50.4 years
(SD=8.3) and in the control group it was 50.3 years
(SD=7.5). The average number of years of work experi-
ence with patients with COPD in the intervention group
was 15.1 years (SD=8.9) and in the control group it was
11.6 years (SD=7.5). In the intervention group and
control group, the numbers of male healthcare provi-
ders were six and nine, respectively.
Thirteen patients dropped out before the baseline
measurement and were excluded from the analyses. A
total of 357 patients completed at least one set of ques-
tionnaires. At 18 months, 305 patients, from 56 clusters,
completed the study (of these 305 patients, 11 patients
did not complete the SGRQ at baseline).
The baseline characteristics of the 357 patients included
in the intervention group and control group are shown in
table 1. Patients from the intervention group showed a
somewhat lower FEV1/FVC ratio, and FEV1%.
Intervention compliance
To check for intervention compliance, we looked at the
number of times the ABC scale was completed, the number
of times a treatment plan was made and the number of
Figure 2 Flow chart of patients in the study. ABC tool, Assessment of Burden of COPD tool; ICR, interquartile range; SGRQ,
St. George’s Respiratory Questionnaire.
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times a personal goal was formulated per patient according
to the registration system of the ABC tool (example in
ﬁgure 1 and box 1). On average, in 18 months, patients
completed the ABC scale 2.7 times (SD=1.3).
Furthermore, on average, a treatment plan was recorded
2.4 times (SD=1.3), and a personal goal was formulated
2.3 times (SD=1.3).
Primary outcome: improvement after 18 months
In the intervention group, 49 (33.6%) patients showed a
clinically relevant improvement, as deﬁned by an
improvement of at least four points, on the SGRQ after
18 months, compared with 33 (22.3%) patients in the
control group. The adjusted odds of a clinically relevant
improvement after 18 months was 1.85 times as high
(95% CI 1.08 to 3.16, p=0.02) in the intervention group
as in the control group (ﬁgure 3). The outcome vari-
ation between care providers was 0.035 (p=0.75), giving
an intraclass correlation coefﬁcient (ICC) of 0.01
according to the ICC deﬁnition for binary outcomes in
Hedeker.28
As sensitivity analysis, a mixed logistic regression ana-
lysis was subsequently performed with the 294 cases with
complete data on the SGRQ at baseline and after
18 months, disregarding the measurements after 6 and
12 months, so that clinical improvement was solely based
on SGRQ at baseline and after 18 months, without bor-
rowing information from other points in time or
patients. This analysis yielded similar results as the previ-
ously mentioned mixed logistic, repeated-measures ana-
lysis of the primary analysis (adjusted OR 1.78, 95% CI
1.02 to 3.10, p=0.04).
Furthermore, since there seemed to be an imbalance
between groups at baseline with respect to FEV1% and
the FEV1/FVC ratio, we repeated the primary intention-
to-treat analysis with FEV1% predicted and FEV1/FVC
ratio added to the model as covariates. This analysis also
resulted in signiﬁcantly higher odds of improvement for
Table 1 Patients’ baseline characteristics
Intervention
group
(n=175)
Control
group
(n=182)
Age, years, mean (SD) 64.8 (8.7) 65.8 (8.8)
Sex, male, % (n) 52.6 (92) 60.4 (110)
Recruiting healthcare provider
Primary care, % (n) 54.9 (96) 63.7 (116)
Hospital care, % (n) 45.1 (79) 36.3 (66)
FEV1/FVC ratio, mean (SD) 48.5 (12.8) 52.1 (11.8)
FEV1, % predicted, mean
(SD)
56.6 (17.8) 62.3 (19.8)
GOLD stage, % (n)
1 (FEV1 >80% predicted) 8.6 (15) 17.0 (31)
2 (FEV1 50–80% predicted) 48.6 (85) 46.7 (85)
3 (FEV1 30–50% predicted) 30.9 (54) 24.2 (44)
4 (FEV1 <30% predicted) 5.1 (9) 2.7 (5)
Missing 6.9 (12) 9.3 (17)
Diagnosed with COPD since, % (n)
1–3 year(s) 33.1 (58) 26.4 (48)
>3 years 62.3 (109) 67.0 (122)
Unknown 4.6 (8) 6.6 (12)
Number of exacerbations in last year, % (n)
0 44.0 (77) 49.5 (90)
1 26.3 (46) 24.7 (45)
2 12.0 (21) 10.4 (19)
>2 13.7 (24) 7.7 (14)
Missing 4.0 (7) 7.7 (14)
Smoking status, % (n)
Current smoker 32.6 (57) 24.7 (45)
Ex-smoker 60.0 (105) 60.4 (110)
Never smoked 5.1 (9) 4.4 (8)
Missing 2.3 (4) 10.4 (19)
Pack-years smoking, mean
(SD)
33.2 (28.3) 30.8 (23.7)
Baseline SGRQ, mean (SD)
Symptoms 49.9 (22.2) 44.2 (25.5)
Activity 44.6 (23.8) 41.4 (24.3)
Impact 24.6 (14.7) 22.8 (15.1)
Total 39.7 (17.8) 36.2 (19.3)
COPD, chronic obstructive pulmonary disease; GOLD, Global
Initiative for Chronic Obstructive Lung Disease; SGRQ,
St. George’s Respiratory Questionnaire.
Figure 3 Comparison of clinically relevant improvement and
deterioration on the SGRQ, after 6, 12 and 18 months
between the intervention and control group, including
percentages of patients at different time points with no
clinically relevant change.
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the intervention group (adjusted OR 1.90, 95% CI 1.07
to 3.38, p=0.03).
Secondary outcomes
Improvement in SGRQ
After 6 months, there was no statistically signiﬁcant dif-
ference between groups with respect to the proportion
of patients with a clinically relevant improvement in
SGRQ (adjusted OR=1.30, 95% CI 0.79 to 2.13, p=0.30).
After 12 months, the adjusted odds of a minimal clinic-
ally relevant improvement in SGRQ was 2.03 times as
high (95% CI 1.20 to 3.41, p<0.01) in the intervention
group as in the control group (see ﬁgure 3).
Deterioration in SGRQ
The adjusted OR of the outcome clinically relevant
deterioration in SGRQ was 0.96 after 6 months (95% CI
0.59 to 1.58, p=0.87). After 12 months, the adjusted odds
of a deterioration in the intervention group was 0.60
times as small as in the control group (95% CI 0.36 to
1.00, p=0.04). After 18 months, the difference between
the intervention group and the control group was in the
same direction as the difference after 12 months
(adjusted OR=0.64, 95% CI 0.39 to 1.04, p=0.07; see
ﬁgure 3).
SGRQ (continuous score)
Table 2 shows the difference between treatment arms
with respect to SGRQ total score and domain scores at
6-month, 12-month and 18-month follow-up, based on
the ﬁnal mixed model, that is, after deleting the group
effect at baseline, which was not signiﬁcant (p=0.195;
for details, see the Statistical Analyses paragraph in the
Methods section). There was no signiﬁcant difference
between treatment arms on the total score after
6 months (−0.90 points: 95% CI −2.85 to 1.05, p=0.37),
but there was a signiﬁcant difference after 12 months
(−2.96 points: 95% CI −4.99 to −0.93, p<0.01) and after
18 months (−3.08 points: 95% CI −5.36 to −0.80,
p<0.01). There was no outcome variation between
healthcare providers, giving an ICC of 0.00. These
results indicate that treatment according to the ABC
tool was associated with better quality of life. For com-
pleteness, we mention that the mixed regression analysis
with the treatment effect at baseline still in the model
gave very similar effect sizes and the same conclusions
about the signiﬁcance of each effect. Figure 4A shows
the change of the observed means in SGRQ total score
after 6-month, 12-month and 18-month follow-up com-
pared with baseline measurement, for both groups.
Since observed means can be biased due to dropout,
ﬁgure 4B shows the change in predicted values based on
the mixed regression model, which is much less prone
to selection bias. The two plots showed almost the same
pattern, that is, an increase in group difference in
favour of intervention up to month 12 and maintenance
of that difference till 18 months.
Additional analyses of the subdomains of the SGRQ
showed that, after 18 months, the intervention group
had a better score on the symptom domain (−4.52
points: 95% CI −8.15 to −0.89, p=0.015). However, this
was just short of signiﬁcance when taking the more
Table 2 Effect of treatment (ABC tool) on the total score and subdomains of the SGRQ at different points in time, as
established with mixed linear regression correcting for age, gender, healthcare setting and smoking status, n=334
Observed score, mean (SD)
β*
95% CI
p ValueIntervention group Control group Lower Upper
SGRQ symptoms
6 months 48.81 (22.83) 43.15 (26.19) −0.83 −3.95 2.30 0.602
12 months 44.65 (21.58) 45.63 (26.27) −5.50 −8.92 −2.07 0.002
18 months 46.16 (23.69) 45.33 (26.46) −4.52 −8.15 −0.89 0.015
SGRQ activity
6 months 45.35 (24.54) 43.36 (25.96) −0.86 −3.74 2.02 0.557
12 months 44.66 (24.92) 43.62 (26.86) −1.12 −4.00 1.77 0.447
18 months 44.23 (26.59) 43.72 (27.45) −2.34 −5.52 0.83 0.147
SGRQ impact
6 months 25.45 (16.24) 23.14 (15.92) 0.23 −1.82 2.29 0.822
12 months 24.43 (15.94) 24.51 (15.59) −1.46 −3.42 0.50 0.144
18 months 23.86 (15.58) 24.68 (17.36) −2.59 −4.66 −0.52 0.014
SGRQ total score
6 months 39.88 (19.09) 36.79 (20.29) −0.90 −2.85 1.05 0.365
12 months 37.91 (18.33) 38.10 (20.80) −2.96 −4.99 −0.93 0.004
18 months 38.39 (19.26) 37.84 (21.92) −3.08 −5.36 −0.80 0.008
*β=mixed linear regression weight for treatment at that point in time. β<0 indicates a lower score in the intervention group. Lower scores or
negative change scores indicate a higher quality of life based on the SGRQ. Effects in this table are based on the mixed model after deleting
the treatment effect at baseline, which was never significant. Effects before deleting the treatment effect were very similar and agreed with the
present table in terms of significance yes/no.
ABC tool, Assessment of Burden of COPD tool; SGRQ, St. George’s Respiratory Questionnaire.
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stringent signiﬁcance level of 1% into account. There
was a signiﬁcant difference in favour of the intervention
group on the subdomain impact (−2.59 points: 95% CI
−4.66 to −0.52, p=0.01), but not on the activity domain
(−2.34 points: 95% CI −5.52 to 0.83, p=0.15).
COPD Assessment Test
The total CAT scores of the treatment groups after
18 months did not differ signiﬁcantly from each other
(−0.26 points: 95% CI −1.52 to 0.99, p=0.68). There was
no outcome variation between healthcare providers,
thus yielding an ICC of 0.00.
Patient Assessment of Chronic Illness Care
The analyses of the PACIC total score showed that treat-
ment had a signiﬁcant effect after 18 months on the
total score of 0.32 points (95% CI 0.14 to 0.50, p<0.01;
see table 3). The outcome variation between healthcare
providers was 0.886 (p=0.08), yielding an ICC of 0.05.
Analyses of the subdomains showed a signiﬁcant differ-
ence between treatment arms at 18 months in all
domains (p<0.01), except for the ‘follow-up/coordin-
ation’ domain (see table 3). These results indicate that
treatment according to the ABC tool increased per-
ceived quality of care as compared with the control
group. Table 3 also displays the results after 12 months.
DISCUSSION
Main findings
We were able to analyse three different outcome mea-
sures related to disease-speciﬁc quality of life and per-
ceived quality of care. We found signiﬁcant differences
between intervention and control arm on the SGRQ
and the PACIC, but not on the CAT.
St. George’s Respiratory Questionnaire
The use of the ABC tool in daily care resulted in more
patients experiencing an improved disease-speciﬁc
quality of life as measured by the SGRQ after a period
of 18 months, compared with usual care. This result was
also found after 12 months, but not after 6 months. The
latter might be explained by the fact that the collabor-
ation between patient and healthcare provider using the
ABC tool requires time and experience to work opti-
mally, and that interventions often also require a behav-
ioural change of the patient. The additional analyses of
the different domains of the SGRQ showed that there
was mainly an improvement in the symptom domain
and the impact domain, but these associations are just
short of signiﬁcance when taking the more stringent
signiﬁcance level of 1% into account to correct for
multiple testing of secondary outcomes.
COPD Assessment Test
We expected to ﬁnd results on the CAT comparable with
the SGRQ since both questionnaires are strongly corre-
lated29–31 and in previous studies the CAT and the
SGRQ usually showed similar results.32–34
Additionally, a systematic review about the CAT29
found that the CAT is a reliable, valid and responsive
instrument. Our study however did not indicate any dif-
ferences between the treatment arms, which might
relate to the fact that most studies evaluating the respon-
siveness of the CAT focused on patients with acute
exacerbations and on patients receiving pulmonary
rehabilitation interventions.35–38 In our study, the ABC
tool was used in stable patients from primary and hos-
pital care. This might indicate that the CAT, compared
with the SGRQ, is less sensitive to change in more stable
situations than the SGRQ.
Figure 4 (A) Mean change in observed SGRQ total scores at 6-month, 12-month and 18-month follow-up compared with
baseline, with a higher score indicating worse quality of life. (B) Mean change in predicted SGRQ total scores at 6-month,
12-month and 18-month follow-up compared with baseline, with a higher score indicating worse quality of life. SGRQ,
St. George’s Respiratory Questionnaire.
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Patient Assessment of Chronic Illness Care
In evaluating the effect of the ABC tool on patients’ per-
ceived quality of care (using the PACIC), a signiﬁcantly
better response was found in the ABC-guided group
compared with the control group. Positive effects on
quality of care were perceived in patient activation, deci-
sion support, goal setting and problem-solving, which
could be expected from the person-centred COPD
approach with the ABC tool. When developing the ABC
tool, the main goal was to make a tool that measures
burden of COPD, and additionally visualises the inte-
grated health status and provides a treatment algorithm.
Furthermore, the tool had to provide room for writing
down a treatment plan including a personal treatment
goal. All of these components are considered to be
important in order to involve the patient in the decision-
making process and help them take control of the
disease, eventually leading to improved self-management
and a better quality of life.39–41
This research in the context of other research
In 2013, Agusti and MacNee advocated more persona-
lised medicine for patients with COPD,42 by suggesting
that healthcare providers need a ‘control panel’ for
the assessment and management of COPD. To our
knowledge, apart from the ABC tool, only one other
instrument has been developed for this purpose,43
although this tool has not yet been evaluated in a ran-
domised trial.
In the management of COPD, interventions are neces-
sary to reduce its burden and prevent its progression.44 45
Although no interventions like the ABC tool were found
in literature,9 many studies have been described evaluat-
ing the effect of behavioural interventions in patients
with COPD on disease-speciﬁc quality of life. These
studies show varying results due to different populations,
methods and interventions.46–54 In many cases, no clinic-
ally relevant or statistically signiﬁcant effect on the
SGRQ was found.50 53–55 Interventions that did result in
signiﬁcant effects on the SGRQ were often much more
demanding and intensive, such as pulmonary rehabilita-
tion programmes,46 47 integrated disease management
programmes,48 thorough proactive self-management
education49 or weekly home visits by health profes-
sionals.50 The ABC tool however is a much more simple
and easy-to-use visual approach that can be deployed as
a communication tool in routine COPD care, facilitating
shared decision-making.56–58
Strengths and limitations
A strength of the study was the fact that it was executed
in almost every province of the Netherlands, in primary
and hospital care, providing information about the
effects of the intervention in different settings and
disease severities. This has positive consequences for the
generalisability of the results and potential implementa-
tion of the ABC tool. Usual care was based on national
guidelines which are in line with international
Table 3 Effect of treatment (ABC tool) on the total score and subdomains of the PACIC at different points in time, as
established with mixed linear regression correcting for age, gender, healthcare setting and smoking status, n=331
Score in intervention
group, mean (SD)
Score in control
group, mean (SD) β*
95% CI
Lower Upper p Value
Activation
12 months 3.26 (1.26) 2.97 (1.22) 0.15 −0.11 0.41 0.267
18 months 3.45 (1.21) 2.90 (1.24) 0.39 0.14 0.65 0.003
Delivery system design
12 months 3.55 (1.07) 3.26 (1.08) 0.19 −0.04 0.43 0.100
18 months 3.73 (1.03) 3.11 (1.10) 0.52 0.30 0.75 <0.001
Goal setting
12 months 3.21 (1.12) 2.57 (1.00) 0.40 0.18 0.61 <0.001
18 months 3.24 (1.05) 2.53 (0.97) 0.50 0.29 0.71 <0.001
Problem-solving
12 months 3.26 (1.18) 2.88 (1.16) 0.22 0.02 0.46 0.068
18 months 3.29 (1.22) 2.76 (1.14) 0.38 0.14 0.62 0.002
Follow-up/coordination
12 months 2.29 (1.13) 2.05 (0.99) 0.12 −0.07 0.31 0.215
18 months 2.29 (1.09) 2.14 (1.08) 0.04 −0.16 0.23 0.708
Total score
12 months 3.09 (1.00) 2.71 (0.91) 0.20 0.02 0.38 0.032
18 months 3.11 (0.95) 2.62 (0.97) 0.32 0.14 0.50 0.001
*β=mixed linear regression weight for treatment at that point in time. β>0 indicates a higher score in the intervention group. Higher scores or
positive change scores indicate a higher perceived quality of care based on the PACIC. Effects in this table are based on the mixed model
after deleting the treatment effect at baseline, which was never significant (see the Methods section). Effects before deleting the treatment
effect were very similar and agreed with the present table in terms of significance yes/no.
ABC tool, Assessment of Burden of COPD tool; PACIC, Patient Assessment of Chronic Illness Care.
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guidelines. However, different usual care in other coun-
tries cannot be excluded, which might affect the gener-
alisability to some extent of our results towards other
countries.
An additional strength was the pragmatic design to
test the effectiveness of the ABC tool in real-life routine
practice, which makes the results more applicable to
daily primary and hospital care. However, the pragmatic
approach also presented challenges. First, the use of the
ABC tool was not actively promoted during the study,
which meant that 4% of the patients did not receive the
intervention. Second, healthcare providers were not
actively stimulated to practice using the tool (if they
requested the opportunity to practice, a dummy account
was provided), since we believed using the tool would be
self-explanatory. It is conceivable that with more training
with the ABC tool, the effect might have been even
greater, and more training might be warranted when
implementing the tool with less motivated/experienced
healthcare providers.
Owing to an error in data collection, smoking status
was not recorded in all patients in the control group at
baseline. However, at the 15-month and 18-month
follow-up, smoking status was recorded and these data
were used to impute the baseline status in patients with
missing smoking status at baseline. To validate this
imputed baseline smoking status, Cohen’s Kappa
measure of agreement was calculated between the
observed and the imputed smoking status in patients
with available baseline data. Kappa was 0.86, indicating
good agreement, and it was therefore concluded that
missing smoking status at baseline could be replaced
with data at the 15-month or 18-month follow-up.
Perhaps due to randomisation at cluster level instead
of individual patient level, there was some imbalance
between both groups at baseline. The intervention
group showed a lower initial lung function. In order to
detect any possible confounding from this imbalance,
we repeated the primary analysis with FEV1% predicted
and forced expiratory ratio (FER) as covariates in the
model. This analysis yielded similar results. Additionally,
on the symptom domain of the SGRQ, the intervention
group seemed to score worse at baseline. However, this
difference was not signiﬁcant and we corrected for this
difference by calculating change scores. Therefore, we
conclude that the results remain unchanged, despite
these imbalances.
When calculating the required sample size, the
expected proportions of patients improved were difﬁcult
to estimate, since little evidence was available on the
effect of disease management interventions on disease-
speciﬁc quality of life as measured by the SGRQ.59
Therefore, the expected proportions of patients
improved were solely based on results of previous drug
trials.60 61 The results from our trial showed that the pro-
portion of patients improved by four points—our
primary outcome—was 33.6% in the intervention group
compared with 22.3% in the control group. Although
this difference was smaller than estimated for the
sample size calculation, it was a statistically signiﬁcant
difference. This is at least partly due to the fact that the
actual dropout rate and the ICC (18% and 0.01, respect-
ively) were lower than expected in the study planning
stage (25% and 0.05, respectively). The smaller than
expected difference in the proportion of patients
improved (11.3% observed vs 20% expected) may partly
be due to the fact that, instead of for example a single
drug intervention, a high variety of interventions were
possible in this trial, which might dilute the effect.
Another possible explanation is the fact that the group
COPD patients included in the study was a stable group
with better quality of life and therefore lower baseline
SGRQ total scores than in other studies, leaving less
room for improvement.62–65
Furthermore, no blinding and allocation concealment
was possible due to the nature of the intervention.
However, the researchers performed the analyses on a
blinded dataset and were therefore unaware of the
coding of treatment arm until unanimous conclusions
had been drawn about the results by all authors.
Implications
This study showed a promising development towards
person-centred care. Visualisation of the integrated
health status seems to be a valid contribution to efforts to
place patients in the driver seat of care planning,
together with their healthcare provider. Future research
should focus on replication of this trial, in other settings
and perhaps for other diseases as well, to investigate the
underlying mechanisms of the effect of the ABC tool and
especially the visually facilitated shared decision-making.
CONCLUSION
Our trial results indicate that the ABC tool has an added
value for patients with COPD. Patients treated with the
ABC tool were more likely to report clinically relevant
improvement in quality of life, as measured by the
SGRQ, compared with patients treated with usual care.
Patients also perceived quality of care as better when the
ABC tool was applied. Further research is necessary to
replicate the results and further investigate the added
value of the ABC tool in different settings.
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